Verified email-pattern data for Stonechecker is currently limited. You can still use the company insights and contact sections below.
StoneChecker Ltd is a health technology company focused on the development and commercialization of products to inform clinical management and to guide care for patients with kidney stones. The company is led by recognized experts in the field of clinical development and commercialization.
More than 300 million patients worldwide suffer with kidney stones and the majority of these are working age adults. Despite these numbers relatively little funding is given to research and development in this field. StoneChecker Ltd aims to address this unmet clinical need by launching two novel products into the healthcare market during 2018.
StoneChecker Ltd is wholly owned by Flying Brands plc; a publicly listed company on the London Stock Exchange.
StoneChecker: Medical Imaging Software for Kidney Stones:
StoneChecker is an innovative medical software designed to aid clinical decision making by providing personalised information about a patient’s kidney stone. Physicians can apply the StoneChecker software to their patient’s diagnostic CT scans to help decide which treatment will be most effective.
StoneChecker Ltd has an exclusive worldwide licence to apply the TexRAD® algorithm (provided by TexRAD, part of Feedback Plc) to examine heterogeneity and ‘texture’ not visible to the naked eye. Tested and validated at the University of Oxford, StoneChecker software will be available for research use in 2017 and commercially available in 2018.
StonePrevent: Screening for the Causes of Kidney Stones:
StonePrevent is a bespoke urine screening programme which aims to identify or exclude certain underlying causes of kidney stones. More than 300 million patients experience a kidney stone episode in their lifetime and as many as 50% have a recurrence. For some patients, there are reversible or addressable causes. After the diagnostic imaging tests and standard blood panel patients receive in hospital, it is recommended patients receive more extensive urine screening.
Working closely with board-certified metabolic physicians who have designed a novel reporting system, StonePrevent will roll out a postal screening service with centralised laboratory facilities that can provide this complex medical service to healthcare services and directly to patients. Commercially available from 2018, StonePrevent will automate, centralise and simplify urine screening.
Company Details
- Founded
- -
- Address
- This Unmet Clinical Need By Launching Two Novel Products Into The Healthcare Market During 2018.
- Industry
- Biotechnology
- Website
- stonechecker.com
Stonechecker Questions
StoneChecker's website is stonechecker.com
StoneChecker's LinkedIn profile is https://www.linkedin.com/company/stonechecker
StoneChecker's industry is
Biotechnology
StoneChecker's top competitors are
Novartis,
Astrazeneca,
Stage Six Inc.,
Albus Health,
Medtronic,
Wellmatch,
Brightinsight,
Dialogue,
Healthworx.
StoneChecker's categories are Biotechnology
StoneChecker's founding year is 2015
Explore related pages
Related company profiles:
Companies like StoneChecker
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.